Physician profile
Tabitha C Lustig
NPI 1184985152
$3,115.76
in general payments reported to CMS, 2019-2025
16 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $699 · 2023: $613 · 2024: $576 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $997.64 | 2021-2025 | Farxiga |
| Abbvie INC. | $593.03 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.61 | 2021-2024 | Jardiance |
| Pfizer INC. | $230.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $224.48 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $207.18 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $162.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $125.19 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.87 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $62.07 | 2021-2023 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $60.08 | 2025 | Inspire |
| Astellas Pharma US INC | $27.32 | 2023 | Veozah |
| Ibsa Pharma INC. | $22.27 | 2023 | Tirosint, Licart |
| Antares Pharma, INC. | $21.94 | 2024 | Xyosted |
| Idorsia Pharmaceuticals US INC | $17.68 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2023 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.